NewsBenzingaHC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $27 HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $27 Benzinga 2026.11.16 12:29 (GMT+0) Open on Benzinga Other news ICE Executive: NYSE Trading Platform Is Ready to Accept Tokens Issued on Solana Suspected Lighter API Key Leak Linked to Market Maker Abraxas Capital; Hyperliquid Short Position Cut to $70M Ledger Brings Clear Signing to Solana, Ending 'Blind' Signing for Jupiter Swaps HKMA, Swift Explore Cross-Border Tokenized Payments FirstSource Stock Outlook: Is Wall Street Bullish or Bearish? What Are Wall Street Analysts' Target Price for Alliant Energy Stock?
Suspected Lighter API Key Leak Linked to Market Maker Abraxas Capital; Hyperliquid Short Position Cut to $70M